skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
CDA Inhibitor E7727/Decitabine Combination Agent ASTX727 (Code C115102)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727

Definition: An orally available combination agent containing the cytidine deaminase (CDA) inhibitor E7727 and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of ASTX727, the CDA inhibitor E7727 binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.

Label: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727

NCI Thesaurus Code: C115102 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL472633  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
CDA Inhibitor E7727/Decitabine Combination Agent ASTX727

External Source Codes: 
PDQ Closed Trial Search ID 759831
PDQ Open Trial Search ID 759831 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C115102
Semantic_Type Nucleic Acid, Nucleoside, or Nucleotide
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom